Suchergebnisse - "Burge, Matthew"

PubPharm (7)

1

Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer : Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group

enthalten in: Clinical colorectal cancer | 2021

von Dunn, C. | Hong, W. | Gibbs, P. | +5

2

Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data

enthalten in: PharmacoEconomics | 2020

von Degeling, K. | Wong, H. | Koffijberg, H. | +14

3

The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab : A translational study [ASCENT

enthalten in: PloS one | 2020

von Clarke, S. | Burge, M. | Feeney, K. | +8

4

Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia : is clinical practice following the evidence?

enthalten in: Internal medicine journal | 2019

von Semira, C. | Wong, H. | Field, K. | +16

5

Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer : Results From a Large International Registry

enthalten in: Clinical colorectal cancer | 2018

von Burge, M. | Semira, C. | Lee, B. | +13

6

Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland

enthalten in: Asia-Pacific journal of clinical oncology | 2017

von Chapman, S. | McKavanagh, D. | Burge, M. | +3

7

The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor : Results from a large prospective cohort study

enthalten in: Asia-Pacific journal of clinical oncology | 2017

von Lee, B. | Wong, H. | Tacey, M. | +18

1
[1]